{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:04:24Z","timestamp":1793239464773,"version":"4.5.0"},"reference-count":225,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guizhou Provincial Health Commission Science and Technology Fund Project","award":["gzwkj2025-300"],"award-info":[{"award-number":["gzwkj2025-300"]}]},{"name":"the Project funded by China Postdoctoral Science Foundation","award":["2022TQ0221"],"award-info":[{"award-number":["2022TQ0221"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472700, 82472745, 82472365, 82373400, 82372660, 82272685, 82202260 and 82173248"],"award-info":[{"award-number":["82472700, 82472745, 82472365, 82373400, 82372660, 82272685, 82202260 and 82173248"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Sichuan University postdoctoral interdisciplinary Innovation Fund","award":["10822041A2103"],"award-info":[{"award-number":["10822041A2103"]}]},{"name":"1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University","award":["ZYGD22006"],"award-info":[{"award-number":["ZYGD22006"]}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"crossref","award":["2024NSFSC1894"],"award-info":[{"award-number":["2024NSFSC1894"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific and Technological Innovation Ability Enhancement Project for Junior Faculties of Sichuan University","award":["2024SCUQJTX043"],"award-info":[{"award-number":["2024SCUQJTX043"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02676-9","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:07:07Z","timestamp":1778069227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Testosterone and cancers: biological functions, molecular mechanisms and therapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhixiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2676_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"2676_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28.","journal-title":"Signal Transduct Target Ther"},{"key":"2676_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Bos PD, Massagu\u00e9 J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274\u201384.","journal-title":"Nat Rev Cancer"},{"key":"2676_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","volume":"14","author":"T Pan","year":"2025","unstructured":"Pan T, Zhang J, Wang X, Song Y. Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021. Exp Hematol Oncol. 2025;14:98.","journal-title":"Exp Hematol Oncol"},{"key":"2676_CR5","unstructured":"Global cancer burden growing. amidst mounting need for services. https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services."},{"key":"2676_CR6","unstructured":"New ACS Cancer Atlas: Global Report Shows Nearly Half of Cancer Mortality Worldwide Attributable to Potentially Modifiable Risk Factors. Am Cancer Soc MediaRoom. https:\/\/pressroom.cancer.org\/2025-06-25-New-ACS-Cancer-Atlas-Global-Report-Shows-Nearly-Half-of-Cancer-Mortality-Worldwide-Attributable-to-Potentially-Modifiable-Risk-Factors."},{"key":"2676_CR7","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1530\/JOE-12-0455","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217:R25\u201345.","journal-title":"J Endocrinol"},{"key":"2676_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/er.2017-00025","volume":"38","author":"AL Goldman","year":"2017","unstructured":"Goldman AL, et al. A Reappraisal of Testosterone\u2019s Binding in Circulation: Physiological and Clinical Implications. Endocr Rev. 2017;38:302\u201324.","journal-title":"Endocr Rev"},{"key":"2676_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/gerona\/glt154","volume":"69","author":"E Bachman","year":"2014","unstructured":"Bachman E, et al. Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin: Evidence for a New Erythropoietin\/Hemoglobin Set Point. J Gerontol Biol Sci Med Sci. 2014;69:725\u201335.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"2676_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506119","author":"PJ Snyder","year":"2016","unstructured":"Snyder PJ, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016. https:\/\/doi.org\/10.1056\/NEJMoa1506119. https:\/\/www.nejm.org\/doi\/full\/.","journal-title":"N Engl J Med"},{"key":"2676_CR11","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1210\/jc.2016-1645","volume":"101","author":"GR Cunningham","year":"2016","unstructured":"Cunningham GR, et al. Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. J Clin Endocrinol Metab. 2016;101:3096\u2013104.","journal-title":"J Clin Endocrinol Metab"},{"key":"2676_CR12","doi-asserted-by":"publisher","first-page":"101141","DOI":"10.1016\/j.molmet.2020.101141","volume":"44","author":"ZL Sebo","year":"2020","unstructured":"Sebo ZL, Rodeheffer MS. Testosterone metabolites differentially regulate obesogenesis and fat distribution. Mol Metab. 2020;44:101141.","journal-title":"Mol Metab"},{"key":"2676_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1053\/j.gastro.2008.05.046","volume":"135","author":"Androgen Receptor Is","year":"2008","unstructured":"Androgen Receptor Is. a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma. Gastroenterology. 2008;135:947\u2013e9555.","journal-title":"Gastroenterology"},{"key":"2676_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccr.2011.05.026","volume":"20","author":"M Ni","year":"2011","unstructured":"Ni M, et al. Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer. Cancer Cell. 2011;20:119\u201331.","journal-title":"Cancer Cell"},{"key":"2676_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fendo.2018.00594","volume":"9","author":"R Bleach","year":"2018","unstructured":"Bleach R, McIlroy M. The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology. Front Endocrinol (Lausanne). 2018;9:594.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2676_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"ME Tan","year":"2015","unstructured":"Tan ME, Li J, Xu HE, Melcher K, Yong E. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36:3\u201323.","journal-title":"Acta Pharmacol Sin"},{"key":"2676_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, et al. Prostate cancer. Lancet. 2016;387:70\u201382.","journal-title":"Lancet"},{"key":"2676_CR18","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1158\/0008-5472.CAN-21-0982","volume":"81","author":"C Aguirre-Portol\u00e9s","year":"2021","unstructured":"Aguirre-Portol\u00e9s C, et al. ZIP9 Is a Druggable Determinant of Sex Differences in Melanoma. Cancer Res. 2021;81:5991\u20136003.","journal-title":"Cancer Res"},{"key":"2676_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/endocrines4020022","volume":"4","author":"D Durovski","year":"2023","unstructured":"Durovski D, Jankovic M, Prekovic S. Insights into Androgen Receptor Action in Lung Cancer. Endocrines. 2023;4:269\u201380.","journal-title":"Endocrines"},{"key":"2676_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cancers9020020","volume":"9","author":"P Li","year":"2017","unstructured":"Li P, Chen J, Miyamoto H. Androgen Receptor Signaling in Bladder Cancer. Cancers (Basel). 2017;9:20.","journal-title":"Cancers (Basel)"},{"key":"2676_CR21","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.3390\/ijms26083548","volume":"26","author":"T Lei","year":"2025","unstructured":"Lei T, Yang Y, Yang W-X. Luteinizing Hormone Regulates Testosterone Production, Leydig Cell Proliferation, Differentiation, and Circadian Rhythm During Spermatogenesis. Int J Mol Sci. 2025;26:3548.","journal-title":"Int J Mol Sci"},{"key":"2676_CR22","doi-asserted-by":"crossref","unstructured":"Huang J, et al. Depression-related testosterone deficiency is linked to reduced cholesterol levels in Leydig cells of CUMS mice. Reproduction. 2024;168(4):e240081.","DOI":"10.1530\/REP-24-0081"},{"key":"2676_CR23","doi-asserted-by":"crossref","unstructured":"Choi Y, et al. Amodiaquine promotes testosterone production and de novo synthesis of cholesterol and triglycerides in Leydig cells. J Lipid Res. 2021;62:100152.","DOI":"10.1016\/j.jlr.2021.100152"},{"key":"2676_CR24","doi-asserted-by":"publisher","first-page":"15555","DOI":"10.3390\/ijms232415555","volume":"23","author":"BM Lawrence","year":"2022","unstructured":"Lawrence BM, O\u2019Donnell L, Smith LB, Rebourcet D. New Insights into Testosterone Biosynthesis: Novel Observations from HSD17B3 Deficient Mice. Int J Mol Sci. 2022;23:15555.","journal-title":"Int J Mol Sci"},{"key":"2676_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/andr.13304","volume":"11","author":"S Garza","year":"2023","unstructured":"Garza S, Papadopoulos V. Testosterone recovery therapy targeting dysfunctional Leydig cells. Andrology. 2023;11:816\u201325.","journal-title":"Andrology"},{"key":"2676_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1210\/er.2017-00091","volume":"38","author":"BD Anawalt","year":"2017","unstructured":"Anawalt BD. Is Dihydrotestosterone a Classic Hormone? Endocr Rev. 2017;38:170\u20132.","journal-title":"Endocr Rev"},{"key":"2676_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1158\/1078-0432.CCR-18-1431","volume":"25","author":"EA Mostaghel","year":"2019","unstructured":"Mostaghel EA, et al. Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer. Clin Cancer Res. 2019;25:426\u201339.","journal-title":"Clin Cancer Res"},{"key":"2676_CR28","first-page":"3","volume":"37","author":"RA Davey","year":"2016","unstructured":"Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016;37:3\u201315.","journal-title":"Clin Biochem Rev"},{"key":"2676_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.steroids.2010.08.008","volume":"76","author":"JS Hackbarth","year":"2011","unstructured":"Hackbarth JS, Hoyne JB, Grebe SK, Singh RJ. Accuracy of calculated free testosterone differs between equations and depends on gender and SHBG concentration. Steroids. 2011;76:48\u201355.","journal-title":"Steroids"},{"key":"2676_CR30","doi-asserted-by":"publisher","first-page":"13521","DOI":"10.3390\/ijms232113521","volume":"23","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance. Int J Mol Sci. 2022;23:13521.","journal-title":"Int J Mol Sci"},{"key":"2676_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/er.2016-1067","volume":"38","author":"RS Swerdloff","year":"2017","unstructured":"Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocr Rev. 2017;38:220\u201354.","journal-title":"Endocr Rev"},{"key":"2676_CR32","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai C, et al. Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors. Cancer Res. 2011;71:6503\u201313.","journal-title":"Cancer Res"},{"key":"2676_CR33","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, et al. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth. Cancer Res. 2008;68:4447\u201354.","journal-title":"Cancer Res"},{"key":"2676_CR34","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","volume":"17","author":"EA Mostaghel","year":"2011","unstructured":"Mostaghel EA, et al. Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913\u201325.","journal-title":"Clin Cancer Res"},{"key":"2676_CR35","doi-asserted-by":"publisher","unstructured":"Sharifi N. The 5\u03b1-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J Investig Med. 2012;60. https:\/\/doi.org\/10.2310\/JIM.0b013e31823874a4.","DOI":"10.2310\/JIM.0b013e31823874a4"},{"key":"2676_CR36","doi-asserted-by":"publisher","first-page":"13728","DOI":"10.1073\/pnas.1107898108","volume":"108","author":"K-H Chang","year":"2011","unstructured":"Chang K-H, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci. 2011;108:13728\u201333.","journal-title":"Proc Natl Acad Sci"},{"key":"2676_CR37","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","volume":"68","author":"JA Locke","year":"2008","unstructured":"Locke JA, et al. Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer. Cancer Res. 2008;68:6407\u201315.","journal-title":"Cancer Res"},{"key":"2676_CR38","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.3390\/nu16234169","volume":"16","author":"J Kim","year":"2024","unstructured":"Kim J, et al. Effect of Elderberry (Sambucus nigra L.) Extract Intake on Normalizing Testosterone Concentration in Testosterone Deficiency Syndrome Rat Model Through Regulation of 17\u03b2-HSD, 5\u03b1-Reductase, and CYP19A1 Expression. Nutrients. 2024;16:4169.","journal-title":"Nutrients"},{"key":"2676_CR39","doi-asserted-by":"publisher","first-page":"105439","DOI":"10.1016\/j.jsbmb.2019.105439","volume":"194","author":"L Schiffer","year":"2019","unstructured":"Schiffer L, et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. J Steroid Biochem Mol Biol. 2019;194:105439.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2676_CR40","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1159\/000491608","volume":"47","author":"Q Deng","year":"2018","unstructured":"Deng Q, et al. CSN6 and Rab34 Are Involved in Androgen Receptor Trafficking in Mouse Testicular Sertoli Cells. Cell Physiol Biochem. 2018;47:2360\u20138.","journal-title":"Cell Physiol Biochem"},{"key":"2676_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000480343","volume":"43","author":"Q Deng","year":"2017","unstructured":"Deng Q, et al. Non-Genomic Action of Androgens is Mediated by Rapid Phosphorylation and Regulation of Androgen Receptor Trafficking. Cell Physiol Biochem. 2017;43:223\u201336.","journal-title":"Cell Physiol Biochem"},{"key":"2676_CR42","doi-asserted-by":"publisher","first-page":"119985","DOI":"10.1016\/j.ijpharm.2020.119985","volume":"591","author":"N Peinetti","year":"2020","unstructured":"Peinetti N, et al. Testosterone-loaded GM1 micelles targeted to the intracellular androgen receptor for the specific induction of genomic androgen signaling. Int J Pharm. 2020;591:119985.","journal-title":"Int J Pharm"},{"key":"2676_CR43","doi-asserted-by":"publisher","unstructured":"Testosterone. (Springer, Heidelberg B, Berlin, Heidelberg. 1998. https:\/\/doi.org\/10.1007\/978-3-642-72185-4.","DOI":"10.1007\/978-3-642-72185-4"},{"key":"2676_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1677\/joe.1.05809","volume":"183","author":"S Ramaswamy","year":"2004","unstructured":"Ramaswamy S, Pohl CR, Marshall GR, Plant TM. A switch from continuous to episodic testicular testosterone release in response to pulsatile LH stimulation in juvenile rhesus monkeys (Macaca mulatta). J Endocrinol. 2004;183:61\u20138.","journal-title":"J Endocrinol"},{"key":"2676_CR45","doi-asserted-by":"publisher","first-page":"e33861","DOI":"10.1371\/journal.pone.0033861","volume":"7","author":"X Liang","year":"2012","unstructured":"Liang X, et al. MicroRNA-34c Enhances Murine Male Germ Cell Apoptosis through Targeting ATF1. PLoS ONE. 2012;7:e33861.","journal-title":"PLoS ONE"},{"key":"2676_CR46","doi-asserted-by":"publisher","first-page":"16696","DOI":"10.1073\/pnas.0506084102","volume":"102","author":"J Meng","year":"2005","unstructured":"Meng J, Holdcraft RW, Shima JE, Griswold MD, Braun RE. Androgens regulate the permeability of the blood\u2013testis barrier. Proc Natl Acad Sci U S A. 2005;102:16696\u2013700.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2676_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1124\/pr.110.002790","volume":"64","author":"CY Cheng","year":"2012","unstructured":"Cheng CY, Mruk DD. The Blood-Testis Barrier and Its Implications for Male Contraception. Pharmacol Rev. 2012;64:16\u201364.","journal-title":"Pharmacol Rev"},{"key":"2676_CR48","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1210\/en.2002-0211","volume":"144","author":"W-Y Lui","year":"2003","unstructured":"Lui W-Y, Wong C-H, Mruk DD, Cheng CY. TGF-\u03b23 Regulates the Blood-Testis Barrier Dynamics via the p38 Mitogen Activated Protein (MAP) Kinase Pathway: An in Vivo Study. Endocrinology. 2003;144:1139\u201342.","journal-title":"Endocrinology"},{"key":"2676_CR49","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1242\/jcs.00900","volume":"117","author":"C Wong","year":"2004","unstructured":"Wong C, Mruk DD, Lui W, Cheng CY. Regulation of blood-testis barrier dynamics: an in vivo study. J Cell Sci. 2004;117:783\u201398.","journal-title":"J Cell Sci"},{"key":"2676_CR50","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1073\/pnas.0308114100","volume":"101","author":"K De Gendt","year":"2004","unstructured":"De Gendt K, et al. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A. 2004;101:1327\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2676_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2605.2010.01061.x","volume":"34","author":"MT Haren","year":"2011","unstructured":"Haren MT, et al. Testosterone modulates gene expression pathways regulating nutrient accumulation, glucose metabolism and protein turnover in mouse skeletal muscle. Int J Androl. 2011;34:55\u201368.","journal-title":"Int J Androl"},{"key":"2676_CR52","first-page":"663","volume":"61","author":"E Edstr\u00f6m","year":"2006","unstructured":"Edstr\u00f6m E, Altun M, H\u00e4gglund M, Ulfhake B. Atrogin-1\/MAFbx and MuRF1 Are Downregulated in Aging-Related Loss of Skeletal Muscle. Journals Gerontology: Ser A. 2006;61:663\u201374.","journal-title":"Journals Gerontology: Ser A"},{"key":"2676_CR53","doi-asserted-by":"publisher","first-page":"e59726","DOI":"10.1371\/journal.pone.0059726","volume":"8","author":"E Castillero","year":"2013","unstructured":"Castillero E, Alamdari N, Aversa Z, Gurav A, Hasselgren P-O. PPAR\u03b2\/\u03b4 Regulates Glucocorticoid- and Sepsis-Induced FOXO1 Activation and Muscle Wasting. PLoS ONE. 2013;8:e59726.","journal-title":"PLoS ONE"},{"key":"2676_CR54","doi-asserted-by":"publisher","first-page":"E469","DOI":"10.1152\/ajpendo.00204.2014","volume":"307","author":"SC Bodine","year":"2014","unstructured":"Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx\/atrogin-1. Am J Physiology-Endocrinology Metabolism. 2014;307:E469\u201384.","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"key":"2676_CR55","doi-asserted-by":"publisher","first-page":"38456","DOI":"10.1074\/jbc.M111.271270","volume":"286","author":"S Wada","year":"2011","unstructured":"Wada S, et al. Translational suppression of atrophic regulators by microRNA-23a integrates resistance to skeletal muscle atrophy. J Biol Chem. 2011;286:38456\u201365.","journal-title":"J Biol Chem"},{"key":"2676_CR56","doi-asserted-by":"publisher","unstructured":"Bhasin S, Wang C, Chandra MS, Gagliano-Juc\u00e1 T, Jasuja R. Mechanisms of Testosterone\u2019s Anabolic Effects on Muscle and Function: Controversies and New Insights. Endocr Rev. 2025;bnaf041. https:\/\/doi.org\/10.1210\/endrev\/bnaf041.","DOI":"10.1210\/endrev\/bnaf041"},{"key":"2676_CR57","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.mce.2012.10.019","volume":"365","author":"JP White","year":"2013","unstructured":"White JP, et al. Testosterone regulation of Akt\/mTORC1\/FoxO3a signaling in skeletal muscle. Mol Cell Endocrinol. 2013;365:174\u201386.","journal-title":"Mol Cell Endocrinol"},{"key":"2676_CR58","unstructured":"\u5b8f\u9152\u4e95, et al. The androgen receptor in mesenchymal progenitors regulates skeletal muscle mass via Igf1 expression in male mice. Proceedings of the National Academy of Sciences. 2024;121:e2407768121."},{"key":"2676_CR59","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1096\/fj.14-249748","volume":"28","author":"V Dubois","year":"2014","unstructured":"Dubois V, et al. A satellite cell-specific knockout of the androgen receptor reveals myostatin as a direct androgen target in skeletal muscle. FASEB J. 2014;28:2979\u201394.","journal-title":"FASEB J"},{"key":"2676_CR60","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1152\/japplphysiol.00490.2009","volume":"108","author":"M Pires-Oliveira","year":"2010","unstructured":"Pires-Oliveira M, et al. Testosterone represses ubiquitin ligases atrogin-1 and Murf-1 expression in an androgen-sensitive rat skeletal muscle in vivo. J Appl Physiol. 2010;108:266\u201373.","journal-title":"J Appl Physiol"},{"key":"2676_CR61","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.febslet.2014.03.051","volume":"588","author":"T Usui","year":"2014","unstructured":"Usui T, et al. Elevated mitochondrial biogenesis in skeletal muscle is associated with testosterone-induced body weight loss in male mice. FEBS Lett. 2014;588:1935\u201341.","journal-title":"FEBS Lett"},{"key":"2676_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1530\/JOE-10-0497","volume":"210","author":"F Salehzadeh","year":"2011","unstructured":"Salehzadeh F, Rune A, Osler M, Al-Khalili L. Testosterone or 17\u03b2-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. J Endocrinol. 2011;210:219\u201329.","journal-title":"J Endocrinol"},{"key":"2676_CR63","doi-asserted-by":"publisher","first-page":"11047","DOI":"10.1096\/fj.201903223RR","volume":"34","author":"N Horii","year":"2020","unstructured":"Horii N, Hasegawa N, Fujie S, Uchida M, Iemitsu M. Resistance exercise-induced increase in muscle 5\u03b1-dihydrotestosterone contributes to the activation of muscle Akt\/mTOR\/p70S6K- and Akt\/AS160\/GLUT4-signaling pathways in type 2 diabetic rats. FASEB J. 2020;34:11047\u201357.","journal-title":"FASEB J"},{"key":"2676_CR64","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"CE Massie","year":"2011","unstructured":"Massie CE, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719\u201333.","journal-title":"EMBO J"},{"key":"2676_CR65","doi-asserted-by":"publisher","first-page":"10105","DOI":"10.1074\/jbc.M600272200","volume":"281","author":"W Zhang","year":"2006","unstructured":"Zhang W, et al. FoxO1 Regulates Multiple Metabolic Pathways in the Liver: Effects on Gluconeogenic, Glycolytic, and Lipogenic gene Expression*. J Biol Chem. 2006;281:10105\u201317.","journal-title":"J Biol Chem"},{"key":"2676_CR66","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.3390\/jcm11133649","volume":"11","author":"R Palma","year":"2022","unstructured":"Palma R, et al. The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. J Clin Med. 2022;11:3649.","journal-title":"J Clin Med"},{"key":"2676_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.apsb.2015.07.009","volume":"6","author":"F Yao","year":"2016","unstructured":"Yao F, Zhang M, Chen L. 5\u2019-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications. Acta Pharm Sinica B. 2016;6:20\u20135.","journal-title":"Acta Pharm Sinica B"},{"key":"2676_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1042\/BJ20101104","volume":"433","author":"J-S Moon","year":"2011","unstructured":"Moon J-S, et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J. 2011;433:225\u201333.","journal-title":"Biochem J"},{"key":"2676_CR69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2020.05.007","volume":"485","author":"J Wang","year":"2020","unstructured":"Wang J, et al. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett. 2020;485:45\u201355.","journal-title":"Cancer Lett"},{"key":"2676_CR70","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1210\/clinem\/dgab616","volume":"107","author":"M Klaver","year":"2022","unstructured":"Klaver M, et al. Change in Visceral Fat and Total Body Fat and the Effect on Cardiometabolic Risk Factors During Transgender Hormone Therapy. J Clin Endocrinol Metabolism. 2022;107:e153\u201364.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2676_CR71","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/obr.12282","volume":"16","author":"DM Kelly","year":"2015","unstructured":"Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581\u2013606.","journal-title":"Obes Rev"},{"key":"2676_CR72","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.steroids.2013.05.001","volume":"78","author":"G Chazenbalk","year":"2013","unstructured":"Chazenbalk G, et al. Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation. Steroids. 2013;78:920\u20136.","journal-title":"Steroids"},{"key":"2676_CR73","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2004-1649","volume":"147","author":"R Singh","year":"2006","unstructured":"Singh R, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006;147:141\u201354.","journal-title":"Endocrinology"},{"key":"2676_CR74","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/jc.2007-1291","volume":"93","author":"CA Allan","year":"2008","unstructured":"Allan CA, Strauss BJG, Burger HG, Forbes EA, McLachlan R. I. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93:139\u201346.","journal-title":"J Clin Endocrinol Metab"},{"key":"2676_CR75","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1210\/jc.2006-1121","volume":"91","author":"ME Wierman","year":"2006","unstructured":"Wierman ME, et al. Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91:3697\u2013710.","journal-title":"J Clin Endocrinol Metab"},{"key":"2676_CR76","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S2213-8587(15)00284-3","volume":"3","author":"SR Davis","year":"2015","unstructured":"Davis SR, Wahlin-Jacobsen S. Testosterone in women\u2014the clinical significance. Lancet Diabetes Endocrinol. 2015;3:980\u201392.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2676_CR77","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1172\/JCI125755","volume":"129","author":"SR Hammes","year":"2019","unstructured":"Hammes SR, Levin ER. Impact of estrogens in males and androgens in females. J Clin Invest. 2019;129:1818\u201326.","journal-title":"J Clin Invest"},{"key":"2676_CR78","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","volume":"23","author":"CA Heinlein","year":"2002","unstructured":"Heinlein CA, Chang C. Androgen Receptor (AR) Coregulators: An Overview. Endocr Rev. 2002;23:175\u2013200.","journal-title":"Endocr Rev"},{"key":"2676_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.yfrne.2007.10.005","volume":"29","author":"CD Foradori","year":"2008","unstructured":"Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocr. 2008;29:169\u201381.","journal-title":"Front Neuroendocr"},{"key":"2676_CR80","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","volume":"25","author":"CA Heinlein","year":"2004","unstructured":"Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276\u2013308.","journal-title":"Endocr Rev"},{"key":"2676_CR81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13293-025-00707-6","volume":"16","author":"ST Barsky","year":"2025","unstructured":"Barsky ST, Monks DA. The role of androgens and global and tissue-specific androgen receptor expression on body composition, exercise adaptation, and performance. Biology Sex Differences. 2025;16:28.","journal-title":"Biology Sex Differences"},{"key":"2676_CR82","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/iju.15424","volume":"31","author":"D Obinata","year":"2024","unstructured":"Obinata D, Takayama K, Inoue S, Takahashi S. Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries. Int J Urol. 2024;31:590\u20137.","journal-title":"Int J Urol"},{"key":"2676_CR83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/pros.20541","volume":"67","author":"AJ Saporita","year":"2007","unstructured":"Saporita AJ, Ai J, Wang Z. The Hsp90 Inhibitor, 17-AAG, Prevents the Ligand-Independent Nuclear Localization of Androgen Receptor in Refractory Prostate Cancer Cells. Prostate. 2007;67:509\u201320.","journal-title":"Prostate"},{"key":"2676_CR84","doi-asserted-by":"publisher","unstructured":"Ainslie RJ, Simitsidellis I, Kirkwood PM, Gibson DA. Rising Stars: Androgens and immune cell function. 2024. https:\/\/doi.org\/10.1530\/JOE-23-0398.","DOI":"10.1530\/JOE-23-0398"},{"key":"2676_CR85","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/cancers11081194","volume":"11","author":"A Hoter","year":"2019","unstructured":"Hoter A, Rizk S, Naim HY. The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer. Cancers (Basel). 2019;11:1194.","journal-title":"Cancers (Basel)"},{"key":"2676_CR86","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fendo.2017.00002","volume":"8","author":"JK Leung","year":"2017","unstructured":"Leung JK, Sadar MD. Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Front Endocrinol (Lausanne). 2017;8:2.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2676_CR87","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.tem.2011.07.006","volume":"22","author":"D Wu","year":"2011","unstructured":"Wu D, Zhang C, Shen Y, Nephew KP, Wang Q. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab. 2011;22:474\u201380.","journal-title":"Trends Endocrinol Metab"},{"key":"2676_CR88","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","volume":"132","author":"M Lupien","year":"2008","unstructured":"Lupien M, et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008;132:958\u201370.","journal-title":"Cell"},{"key":"2676_CR89","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/ng.3419","volume":"47","author":"MM Pomerantz","year":"2015","unstructured":"Pomerantz MM, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47:1346\u201351.","journal-title":"Nat Genet"},{"key":"2676_CR90","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, et al. The PI3K Pathway in Human Disease. Cell. 2017;170:605\u201335.","journal-title":"Cell"},{"key":"2676_CR91","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168:960\u201376.","journal-title":"Cell"},{"key":"2676_CR92","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3390\/ijms24032289","volume":"24","author":"F Raith","year":"2023","unstructured":"Raith F, O\u2019Donovan DH, Lemos C, Politz O, Haendler B. Addressing the Reciprocal Crosstalk between the AR and the PI3K\/AKT\/mTOR Signaling Pathways for Prostate Cancer Treatment. Int J Mol Sci. 2023;24:2289.","journal-title":"Int J Mol Sci"},{"key":"2676_CR93","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, et al. Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell. 2011;19:575\u201386.","journal-title":"Cancer Cell"},{"key":"2676_CR94","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/1535-7163.MCT-17-0111","volume":"16","author":"MA Gordon","year":"2017","unstructured":"Gordon MA, et al. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. Mol Cancer Ther. 2017;16:1389\u2013400.","journal-title":"Mol Cancer Ther"},{"key":"2676_CR95","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.drudis.2021.02.001","volume":"26","author":"H Zhang","year":"2021","unstructured":"Zhang H, Spencer K, Burley SK, Zheng XF. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov Today. 2021;26:1539\u201346.","journal-title":"Drug Discov Today"},{"key":"2676_CR96","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/hep.20474","volume":"40","author":"Groupe d\u2019Etude et de Traitement du Carcinome H\u00e9patocellulaire","year":"2004","unstructured":"Groupe d\u2019Etude et de Traitement du Carcinome H\u00e9patocellulaire. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology. 2004;40:1361\u20139.","journal-title":"Hepatology"},{"key":"2676_CR97","doi-asserted-by":"publisher","first-page":"e1825","DOI":"10.1634\/theoncologist.2020-0521","volume":"25","author":"JJ Harding","year":"2020","unstructured":"Harding JJ, et al. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2020;25:e1825\u201336.","journal-title":"Oncologist"},{"key":"2676_CR98","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/hep.29715","volume":"67","author":"H Zhang","year":"2018","unstructured":"Zhang H, et al. Significance and mechanism of androgen receptor overexpression and androgen receptor\/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology. 2018;67:2271\u201386.","journal-title":"Hepatology"},{"key":"2676_CR99","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1101\/gad.299958.117","volume":"31","author":"\u00c9 Audet-Walsh","year":"2017","unstructured":"Audet-Walsh \u00c9, et al. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes Dev. 2017;31:1228\u201342.","journal-title":"Genes Dev"},{"key":"2676_CR100","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/1541-7786.MCR-23-0087","volume":"22","author":"Y Chen","year":"2024","unstructured":"Chen Y, Han L, Dufour CR, Alfonso A, Gigu\u00e8re V. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent Prostate Cancer Cells. Mol Cancer Res. 2024;22:113\u201324.","journal-title":"Mol Cancer Res"},{"key":"2676_CR101","doi-asserted-by":"crossref","unstructured":"Dufour CR, et al. The mTOR chromatin-bound interactome in prostate cancer. Cell Rep. 2022;38(10):110448.","DOI":"10.1016\/j.celrep.2022.110534"},{"key":"2676_CR102","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/hep.32120","volume":"75","author":"Q Ren","year":"2022","unstructured":"Ren Q, et al. Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis. Hepatology. 2022;75:1123\u201338.","journal-title":"Hepatology"},{"key":"2676_CR103","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X. Wnt\/\u03b2-Catenin Signaling: Components, Mechanisms, and Diseases. Dev Cell. 2009;17:9\u201326.","journal-title":"Dev Cell"},{"key":"2676_CR104","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R. Wnt\/\u03b2-Catenin Signaling and Disease. Cell. 2012;149:1192\u2013205.","journal-title":"Cell"},{"key":"2676_CR105","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrm3470","volume":"13","author":"C Niehrs","year":"2012","unstructured":"Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13:767\u201379.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2676_CR106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","volume":"16","author":"MJ Perugorria","year":"2019","unstructured":"Perugorria MJ, et al. Wnt\u2013\u03b2-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16:121\u201336.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2676_CR107","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/ncb2048","volume":"12","author":"L Vermeulen","year":"2010","unstructured":"Vermeulen L, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12:468\u201376.","journal-title":"Nat Cell Biol"},{"key":"2676_CR108","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","volume":"102","author":"Y Wu","year":"2010","unstructured":"Wu Y, Zhou BP. TNF-\u03b1\/NF-\u03baB\/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102:639\u201344.","journal-title":"Br J Cancer"},{"key":"2676_CR109","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial\u2013mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2676_CR110","doi-asserted-by":"publisher","first-page":"8453","DOI":"10.1038\/sj.onc.1206049","volume":"21","author":"DR Chesire","year":"2002","unstructured":"Chesire DR, Isaacs WB. Ligand-dependent inhibition of beta-catenin\/TCF signaling by androgen receptor. Oncogene. 2002;21:8453\u201369.","journal-title":"Oncogene"},{"key":"2676_CR111","doi-asserted-by":"publisher","first-page":"30828","DOI":"10.1074\/jbc.M301208200","volume":"278","author":"AL Amir","year":"2003","unstructured":"Amir AL, et al. A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem. 2003;278:30828\u201334.","journal-title":"J Biol Chem"},{"key":"2676_CR112","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/pros.22828","volume":"74","author":"L Antony","year":"2014","unstructured":"Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen Receptor (AR) Suppresses Normal Human Prostate Epithelial Cell Proliferation via AR\/\u03b2-catenin\/TCF-4 Complex Inhibition of c-MYC Transcription. Prostate. 2014;74:1118\u201331.","journal-title":"Prostate"},{"key":"2676_CR113","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1128\/MCB.26.3.929-939.2006","volume":"26","author":"S-Y Chen","year":"2006","unstructured":"Chen S-Y, et al. Activation of \u03b2-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-\u03b2-Catenin Interaction. Mol Cell Biol. 2006;26:929\u201339.","journal-title":"Mol Cell Biol"},{"key":"2676_CR114","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ebiom.2018.08.043","volume":"35","author":"H Song","year":"2018","unstructured":"Song H, et al. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt\/\u03b2-catenin signaling. EBioMedicine. 2018;35:155\u201366.","journal-title":"EBioMedicine"},{"key":"2676_CR115","doi-asserted-by":"publisher","first-page":"15710","DOI":"10.1073\/pnas.1218168110","volume":"110","author":"E Lee","year":"2013","unstructured":"Lee E, et al. Inhibition of androgen receptor and \u03b2-catenin activity in prostate cancer. Proc Natl Acad Sci U S A. 2013;110:15710\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2676_CR116","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","volume":"78","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, et al. Inhibition of the Wnt\/\u03b2-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Cancer Res. 2018;78:3147\u201362.","journal-title":"Cancer Res"},{"key":"2676_CR117","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/mc.23565","volume":"62","author":"IM Atawia","year":"2023","unstructured":"Atawia IM, et al. Inhibition of Wnt\/\u03b2-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. Mol Carcinog. 2023;62:1312\u201324.","journal-title":"Mol Carcinog"},{"key":"2676_CR118","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","volume":"66","author":"ERK1\/2 MAP kinases","year":"2012","unstructured":"ERK1\/2 MAP kinases. Structure, function, and regulation. Pharmacol Res. 2012;66:105\u201343.","journal-title":"Pharmacol Res"},{"key":"2676_CR119","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279\u201390.","journal-title":"Oncogene"},{"key":"2676_CR120","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2676_CR121","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar AA, Poulikakos PI. Targeting RAS\u2013ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13:928\u201342.","journal-title":"Nat Rev Drug Discov"},{"key":"2676_CR122","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/cells11060952","volume":"11","author":"KJ Miller","year":"2022","unstructured":"Miller KJ, Asim M. Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer. Cells. 2022;11:952.","journal-title":"Cells"},{"key":"2676_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Sig Transduct Target Ther. 2021;6:1\u201333.","journal-title":"Sig Transduct Target Ther"},{"key":"2676_CR124","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1126\/science.1071545","volume":"296","author":"DS Aaronson","year":"2002","unstructured":"Aaronson DS, Horvath CM. A Road Map for Those Who Don\u2019t Know JAK-STAT. Science. 2002;296:1653\u20135.","journal-title":"Science"},{"key":"2676_CR125","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Reviews Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Reviews Clin Oncol"},{"key":"2676_CR126","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798\u2013809.","journal-title":"Nat Rev Cancer"},{"key":"2676_CR127","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36\u201349.","journal-title":"Nat Rev Immunol"},{"key":"2676_CR128","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2676_CR129","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"2676_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00190-9","volume":"6","author":"AR Michmerhuizen","year":"2020","unstructured":"Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW. ARe we there yet? Understanding androgen receptor signaling in breast cancer. npj Breast Cancer. 2020;6:1\u201319.","journal-title":"npj Breast Cancer"},{"key":"2676_CR131","doi-asserted-by":"publisher","first-page":"113461","DOI":"10.1016\/j.celrep.2023.113461","volume":"42","author":"S Asemota","year":"2023","unstructured":"Asemota S, et al. Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype. Cell Rep. 2023;42:113461.","journal-title":"Cell Rep"},{"key":"2676_CR132","doi-asserted-by":"publisher","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu J, Lin H, Wu G, Zhu M, Li M. IL-6\/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma. Front Oncol. 2021;11:760971.","journal-title":"Front Oncol"},{"key":"2676_CR133","doi-asserted-by":"publisher","first-page":"866014","DOI":"10.3389\/fonc.2022.866014","volume":"12","author":"SG Manore","year":"2022","unstructured":"Manore SG, Doheny DL, Wong GL, Lo H-W. IL-6\/JAK\/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. Front Oncol. 2022;12:866014.","journal-title":"Front Oncol"},{"key":"2676_CR134","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/0008-5472.CAN-13-0594","volume":"74","author":"A Schroeder","year":"2014","unstructured":"Schroeder A, et al. Loss of Androgen Receptor Expression Promotes a Stem-Like Cell Phenotype in Prostate Cancer through STAT3 Signaling. Cancer Res. 2014;74:1227\u201337.","journal-title":"Cancer Res"},{"key":"2676_CR135","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736\u201346.","journal-title":"Nat Rev Cancer"},{"key":"2676_CR136","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"F-X Yu","year":"2015","unstructured":"Yu F-X, Zhao B, Guan K-L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015;163:811\u201328.","journal-title":"Cell"},{"key":"2676_CR137","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma S, Meng Z, Chen R, Guan K-L. The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem. 2019;88:577\u2013604.","journal-title":"Annu Rev Biochem"},{"key":"2676_CR138","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1073\/pnas.0911409107","volume":"107","author":"H Song","year":"2010","unstructured":"Song H, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci. 2010;107:1431\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"2676_CR139","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","volume":"19","author":"D Pan","year":"2010","unstructured":"Pan D. The Hippo Signaling Pathway in Development and Cancer. Dev Cell. 2010;19:491\u2013505.","journal-title":"Dev Cell"},{"key":"2676_CR140","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246\u201357.","journal-title":"Nat Rev Cancer"},{"key":"2676_CR141","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi T, Hansen CG, Guan K-L. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73\u20139.","journal-title":"Nat Rev Cancer"},{"key":"2676_CR142","doi-asserted-by":"publisher","first-page":"e112184","DOI":"10.15252\/embj.2022112184","volume":"42","author":"X Li","year":"2023","unstructured":"Li X, et al. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth. EMBO J. 2023;42:e112184.","journal-title":"EMBO J"},{"key":"2676_CR143","doi-asserted-by":"publisher","first-page":"e202201620","DOI":"10.26508\/lsa.202201620","volume":"6","author":"O Salem","year":"2023","unstructured":"Salem O, Jia S, Qian B-Z, Hansen CG. AR activates YAP\/TAZ differentially in prostate cancer. Life Sci Alliance. 2023;6:e202201620.","journal-title":"Life Sci Alliance"},{"key":"2676_CR144","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","volume":"25","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep. 2018;25:1304\u2013e13175.","journal-title":"Cell Rep"},{"key":"2676_CR145","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016;2:1441\u20139.","journal-title":"JAMA Oncol"},{"key":"2676_CR146","doi-asserted-by":"crossref","unstructured":"Armstrong AJ, et al. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020;4:PO.20.00200.","DOI":"10.1200\/PO.20.00200"},{"key":"2676_CR147","doi-asserted-by":"crossref","unstructured":"Peinetti N, Bilusic M, Burnstein KL. Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy? J Clin Invest. 2022;132(15):e157880.","DOI":"10.1172\/JCI165357"},{"key":"2676_CR148","first-page":"215","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9 J. TGF\u03b2 Cancer Cell. 2008;134:215\u201330.","journal-title":"TGF\u03b2 Cancer Cell"},{"key":"2676_CR149","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.cco.0000143682.45316.ae","volume":"17","author":"KE Bachman","year":"2005","unstructured":"Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr Opin Oncol. 2005;17:49\u201354.","journal-title":"Curr Opin Oncol"},{"key":"2676_CR150","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.7150\/thno.51383","volume":"11","author":"J Chen","year":"2021","unstructured":"Chen J, et al. Targeting transforming growth factor-\u03b2 signaling for enhanced cancer chemotherapy. Theranostics. 2021;11:1345\u201363.","journal-title":"Theranostics"},{"key":"2676_CR151","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/hep.25644","volume":"56","author":"W-L Ma","year":"2012","unstructured":"Ma W-L, et al. Hepatic Androgen Receptor Suppresses Hepatocellular Carcinoma Metastasis Through Modulation of Cell Migration and Anoikis. Hepatology. 2012;56:176\u201385.","journal-title":"Hepatology"},{"key":"2676_CR152","doi-asserted-by":"publisher","first-page":"R165","DOI":"10.1530\/ERC-13-0283","volume":"21","author":"W-L Ma","year":"2014","unstructured":"Ma W-L, Lai H-C, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, cirrhosis, and hepatitis. Endocr Relat Cancer. 2014;21:R165\u201382.","journal-title":"Endocr Relat Cancer"},{"key":"2676_CR153","doi-asserted-by":"crossref","unstructured":"Xu L, et al. The Hepatoprotective and Hepatotoxic Roles of Sex and Sex-Related Hormones. Front Immunol. 2022;13:939270.","DOI":"10.3389\/fimmu.2022.939631"},{"key":"2676_CR154","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/jcb.20638","volume":"97","author":"G Yoon","year":"2006","unstructured":"Yoon G, Kim JY, Choi YK, Won YS, Lim IK. Direct activation of TGF-beta1 transcription by androgen and androgen receptor complex in Huh7 human hepatoma cells and its tumor in nude mice. J Cell Biochem. 2006;97:393\u2013411.","journal-title":"J Cell Biochem"},{"key":"2676_CR155","first-page":"187","volume":"2","author":"RS Liao","year":"2013","unstructured":"Liao RS, et al. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol. 2013;2:187\u201396.","journal-title":"Transl Androl Urol"},{"key":"2676_CR156","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1038\/s41598-019-41016-4","volume":"9","author":"P Giovannelli","year":"2019","unstructured":"Giovannelli P, Di Donato M, Auricchio F, Castoria G, Migliaccio A. Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR\/Src\/PI3-K Complex Assembly. Sci Rep. 2019;9:4490.","journal-title":"Sci Rep"},{"key":"2676_CR157","doi-asserted-by":"crossref","unstructured":"Di Donato M, et al. Non-Genomic Androgen Action Regulates Proliferative\/Migratory Signaling in Stromal Cells. Front Endocrinol. 2015;5:225.","DOI":"10.3389\/fendo.2014.00225"},{"key":"2676_CR158","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1083\/jcb.200211099","volume":"161","author":"G Castoria","year":"2003","unstructured":"Castoria G, et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol. 2003;161:547\u201356.","journal-title":"J Cell Biol"},{"key":"2676_CR159","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1038\/sj.onc.1203028","volume":"18","author":"ME Bala\u00f1\u00e1","year":"1999","unstructured":"Bala\u00f1\u00e1 ME, Lupu R, Labriola L, Charreau EH, Elizalde PV. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene. 1999;18:6370\u20139.","journal-title":"Oncogene"},{"key":"2676_CR160","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1093\/emboj\/19.20.5406","volume":"19","author":"A Migliaccio","year":"2000","unstructured":"Migliaccio A, et al. Steroid-induced androgen receptor\u2013oestradiol receptor \u03b2\u2013Src complex triggers prostate cancer cell proliferation. EMBO J. 2000;19:5406\u201317.","journal-title":"EMBO J"},{"key":"2676_CR161","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4161\/spmg.1.2.16956","volume":"1","author":"WH Walker","year":"2011","unstructured":"Walker WH. Testosterone signaling and the regulation of spermatogenesis. Spermatogenesis. 2011;1:116\u201320.","journal-title":"Spermatogenesis"},{"key":"2676_CR162","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/sj.onc.1203032","volume":"18","author":"H Peterziel","year":"1999","unstructured":"Peterziel H, et al. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene. 1999;18:6322\u20139.","journal-title":"Oncogene"},{"key":"2676_CR163","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1593\/neo.101324","volume":"13","author":"KM Chia","year":"2011","unstructured":"Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia. 2011;13:154\u201366.","journal-title":"Neoplasia"},{"key":"2676_CR164","doi-asserted-by":"publisher","first-page":"e1548","DOI":"10.1038\/cddis.2014.497","volume":"5","author":"G Castoria","year":"2014","unstructured":"Castoria G, et al. Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells. Cell Death Dis. 2014;5:e1548\u20131548.","journal-title":"Cell Death Dis"},{"key":"2676_CR165","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.1843810","volume":"24","author":"B Zhao","year":"2010","unstructured":"Zhao B, Li L, Tumaneng K, Wang C-Y, Guan. K.-L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF\u03b2-TRCP. Genes Dev. 2010;24:72\u201385.","journal-title":"Genes Dev"},{"key":"2676_CR166","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1101\/gad.1602907","volume":"21","author":"B Zhao","year":"2007","unstructured":"Zhao B, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747\u201361.","journal-title":"Genes Dev"},{"key":"2676_CR167","doi-asserted-by":"publisher","first-page":"44418","DOI":"10.1038\/srep44418","volume":"7","author":"K Kalyvianaki","year":"2017","unstructured":"Kalyvianaki K, et al. Antagonizing effects of membrane-acting androgens on the eicosanoid receptor OXER1 in prostate cancer. Sci Rep. 2017;7:44418.","journal-title":"Sci Rep"},{"key":"2676_CR168","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1210\/jc.2004-0801","volume":"90","author":"A Hatzoglou","year":"2005","unstructured":"Hatzoglou A, et al. Membrane Androgen Receptor Activation Induces Apoptotic Regression of Human Prostate Cancer Cells in Vitro and in Vivo. J Clin Endocrinol Metab. 2005;90:893\u2013903.","journal-title":"J Clin Endocrinol Metab"},{"key":"2676_CR169","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40842-020-00106-3","volume":"6","author":"SJ Winters","year":"2020","unstructured":"Winters SJ. SHBG and total testosterone levels in men with adult onset hypogonadism: what are we overlooking? Clin Diabetes Endocrinol. 2020;6:17.","journal-title":"Clin Diabetes Endocrinol"},{"key":"2676_CR170","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1210\/en.2014-1201","volume":"155","author":"P Thomas","year":"2014","unstructured":"Thomas P, Pang Y, Dong J, Berg AH. Identification and Characterization of Membrane Androgen Receptors in the ZIP9 Zinc Transporter Subfamily: II. Role of Human ZIP9 in Testosterone-Induced Prostate and Breast Cancer Cell Apoptosis. Endocrinology. 2014;155:4250\u201365.","journal-title":"Endocrinology"},{"key":"2676_CR171","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1124\/mol.118.115014","volume":"95","author":"R Ye","year":"2019","unstructured":"Ye R, Pi M, Nooh MM, Bahout SW, Quarles LD. Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells. Mol Pharmacol. 2019;95:563\u201372.","journal-title":"Mol Pharmacol"},{"key":"2676_CR172","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/en.2014-1198","volume":"155","author":"AH Berg","year":"2014","unstructured":"Berg AH, Rice CD, Rahman MS, Dong J, Thomas P. Identification and Characterization of Membrane Androgen Receptors in the ZIP9 Zinc Transporter Subfamily: I. Discovery in Female Atlantic Croaker and Evidence ZIP9 Mediates Testosterone-Induced Apoptosis of Ovarian Follicle Cells. Endocrinology. 2014;155:4237\u201349.","journal-title":"Endocrinology"},{"key":"2676_CR173","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mce.2017.02.025","volume":"447","author":"P Thomas","year":"2017","unstructured":"Thomas P, Pang Y, Dong J. Membrane androgen receptor characteristics of human ZIP9 (SLC39A) zinc transporter in prostate cancer cells: Androgen-specific activation and involvement of an inhibitory G protein in zinc and MAP kinase signaling. Mol Cell Endocrinol. 2017;447:23\u201334.","journal-title":"Mol Cell Endocrinol"},{"key":"2676_CR174","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygcen.2017.04.016","volume":"257","author":"P Thomas","year":"2018","unstructured":"Thomas P, Converse A, Berg HA. ZIP9, a novel membrane androgen receptor and zinc transporter protein. Gen Comp Endocrinol. 2018;257:130\u20136.","journal-title":"Gen Comp Endocrinol"},{"key":"2676_CR175","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1210\/en.2017-00087","volume":"158","author":"A Converse","year":"2017","unstructured":"Converse A, Zhang C, Thomas P. Membrane Androgen Receptor ZIP9 Induces Croaker Ovarian Cell Apoptosis via Stimulatory G Protein Alpha Subunit and MAP Kinase Signaling. Endocrinology. 2017;158:3015\u201329.","journal-title":"Endocrinology"},{"key":"2676_CR176","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1210\/jc.2016-2935","volume":"102","author":"TG Travison","year":"2017","unstructured":"Travison TG, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102:1161\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"2676_CR177","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/biolre\/ioz086","volume":"101","author":"A Converse","year":"2019","unstructured":"Converse A, Thomas P. Androgens regulate follicle stage-dependent pro- and anti-apoptosis in teleost ovaries through ZIP9 activation of different G proteins\u2020. Biol Reprod. 2019;101:377\u201391.","journal-title":"Biol Reprod"},{"key":"2676_CR178","doi-asserted-by":"publisher","first-page":"bvad1141757","DOI":"10.1210\/jendso\/bvad114.1757","volume":"7","author":"P Thomas","year":"2023","unstructured":"Thomas P. SAT019 Ligand-independent Signaling And Migration Of Breast Cancer Cells Overexpressing Membrane Androgen Receptor, ZIP9. J Endocr Soc. 2023;7:bvad1141757.","journal-title":"J Endocr Soc"},{"key":"2676_CR179","doi-asserted-by":"publisher","first-page":"39953","DOI":"10.1074\/jbc.M110.158063","volume":"285","author":"M Pi","year":"2010","unstructured":"Pi M, Parrill AL, Quarles LD. GPRC6A Mediates the Non-genomic Effects of Steroids *. J Biol Chem. 2010;285:39953\u201364.","journal-title":"J Biol Chem"},{"key":"2676_CR180","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molmet.2016.12.006","volume":"6","author":"M Pi","year":"2017","unstructured":"Pi M, Nishimoto SK, Quarles LD. GPRC6A: Jack of all metabolism (or master of none). Mol Metabolism. 2017;6:185\u201393.","journal-title":"Mol Metabolism"},{"key":"2676_CR181","doi-asserted-by":"publisher","first-page":"19432","DOI":"10.1038\/s41598-019-55941-x","volume":"9","author":"L De Toni","year":"2019","unstructured":"De Toni L, et al. SHBG141\u2013161 Domain-Peptide Stimulates GPRC6A-Mediated Response in Leydig and \u03b2-Langerhans cell lines. Sci Rep. 2019;9:19432.","journal-title":"Sci Rep"},{"key":"2676_CR182","doi-asserted-by":"publisher","first-page":"bqab011","DOI":"10.1210\/endocr\/bqab011","volume":"162","author":"M Pi","year":"2021","unstructured":"Pi M, Nishimoto SK. Darryl Quarles, L. Explaining Divergent Observations Regarding Osteocalcin\/GPRC6A Endocrine Signaling. Endocrinology. 2021;162:bqab011.","journal-title":"Endocrinology"},{"key":"2676_CR183","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13046-017-0561-x","volume":"36","author":"R Ye","year":"2017","unstructured":"Ye R, Pi M, Cox JV, Nishimoto SK, Quarles L. D. CRISPR\/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model. J Exp Clin Cancer Res. 2017;36:90.","journal-title":"J Exp Clin Cancer Res"},{"key":"2676_CR184","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1210\/me.2015-1161","volume":"29","author":"M Pi","year":"2015","unstructured":"Pi M, et al. Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. Mol Endocrinol. 2015;29:1759\u201373.","journal-title":"Mol Endocrinol"},{"key":"2676_CR185","first-page":"3529","volume":"30","author":"H Foster","year":"2010","unstructured":"Foster H, et al. Differential Expression of mTOR Signalling Components in Drug Resistance in Ovarian Cancer. Anticancer Res. 2010;30:3529\u201334.","journal-title":"Anticancer Res"},{"key":"2676_CR186","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 2020;21:4507.","journal-title":"Int J Mol Sci"},{"key":"2676_CR187","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/pros.21442","volume":"72","author":"M Pi","year":"2012","unstructured":"Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate. 2012;72:399\u2013409.","journal-title":"Prostate"},{"key":"2676_CR188","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/molecules29010224","volume":"29","author":"K Kalyvianaki","year":"2024","unstructured":"Kalyvianaki K, et al. 5-Oxo-ETE\/OXER1: A Link between Tumor Cells and Macrophages Leading to Regulation of Migration. Molecules. 2024;29:224.","journal-title":"Molecules"},{"key":"2676_CR189","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.molonc.2010.01.004","volume":"4","author":"V Pelekanou","year":"2010","unstructured":"Pelekanou V, et al. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR. Mol Oncol. 2010;4:135\u201349.","journal-title":"Mol Oncol"},{"key":"2676_CR190","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.steroids.2019.01.006","volume":"142","author":"Membrane androgen","year":"2019","unstructured":"Membrane androgen. receptors (OXER1, GPRC6A AND ZIP9) in prostate and breast cancer: A comparative study of their expression. Steroids. 2019;142:100\u20138.","journal-title":"Steroids"},{"key":"2676_CR191","doi-asserted-by":"publisher","first-page":"111487","DOI":"10.1016\/j.mce.2021.111487","volume":"539","author":"AA Panagiotopoulos","year":"2022","unstructured":"Panagiotopoulos AA, et al. OXER1 mediates testosterone-induced calcium responses in prostate cancer cells. Mol Cell Endocrinol. 2022;539:111487.","journal-title":"Mol Cell Endocrinol"},{"key":"2676_CR192","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41389-020-00291-x","volume":"9","author":"M Masi","year":"2020","unstructured":"Masi M, et al. OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression. Oncogenesis. 2020;9:105.","journal-title":"Oncogenesis"},{"key":"2676_CR193","doi-asserted-by":"publisher","first-page":"29664","DOI":"10.1021\/acsomega.1c04027","volume":"6","author":"AA Panagiotopoulos","year":"2021","unstructured":"Panagiotopoulos AA, et al. New Antagonists of the Membrane Androgen Receptor OXER1 from the ZINC Natural Product Database. ACS Omega. 2021;6:29664\u201374.","journal-title":"ACS Omega"},{"key":"2676_CR194","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/oncolo\/oyad055","volume":"28","author":"SR Denmeade","year":"2023","unstructured":"Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. Oncologist. 2023;28:465\u201373.","journal-title":"Oncologist"},{"key":"2676_CR195","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1470-2045(17)30907-5","volume":"19","author":"CP Evans","year":"2018","unstructured":"Evans CP. Bipolar androgen therapy: an intriguing paradox. Lancet Oncol. 2018;19:8\u201310.","journal-title":"Lancet Oncol"},{"key":"2676_CR196","doi-asserted-by":"publisher","first-page":"64447","DOI":"10.18632\/oncotarget.10901","volume":"7","author":"KM Wadosky","year":"2016","unstructured":"Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016;7:64447\u201370.","journal-title":"Oncotarget"},{"key":"2676_CR197","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.eururo.2017.03.022","volume":"72","author":"MT Schweizer","year":"2017","unstructured":"Schweizer MT, Antonarakis ES, Denmeade SR. Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. Eur Urol. 2017;72:323\u20135.","journal-title":"Eur Urol"},{"key":"2676_CR198","doi-asserted-by":"crossref","unstructured":"You X, et al. Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: a systematic review. Front Endocrinol. 2023;13:1116800.","DOI":"10.3389\/fendo.2022.1125838"},{"key":"2676_CR199","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3390\/biomedicines11072084","volume":"11","author":"N Nabavi","year":"2023","unstructured":"Nabavi N, et al. Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire. Biomedicines. 2023;11:2084.","journal-title":"Biomedicines"},{"key":"2676_CR200","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","volume":"19","author":"BA Teply","year":"2018","unstructured":"Teply BA, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018;19:76\u201386.","journal-title":"Lancet Oncol"},{"key":"2676_CR201","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.eururo.2020.06.042","volume":"79","author":"MC Markowski","year":"2021","unstructured":"Markowski MC, et al. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. Eur Urol. 2021;79:692\u20139.","journal-title":"Eur Urol"},{"key":"2676_CR202","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"2676_CR203","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"2676_CR204","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.20.02759","volume":"39","author":"SR Denmeade","year":"2021","unstructured":"Denmeade SR, et al. Transformer: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021;39:1371\u201382.","journal-title":"J Clin Oncol"},{"key":"2676_CR205","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41467-023-44514-2","volume":"15","author":"MC Markowski","year":"2024","unstructured":"Markowski MC, et al. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nat Commun. 2024;15:14.","journal-title":"Nat Commun"},{"key":"2676_CR206","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/pros.24529","volume":"83","author":"SA Caputo","year":"2023","unstructured":"Caputo SA, et al. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer. Prostate. 2023;83:879\u201385.","journal-title":"Prostate"},{"key":"2676_CR207","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.euros.2022.05.006","volume":"41","author":"MC Markowski","year":"2022","unstructured":"Markowski MC, et al. Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. Eur Urol Open Sci. 2022;41:112\u20135.","journal-title":"Eur Urol Open Sci"},{"key":"2676_CR208","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/oncotarget.2831","volume":"6","author":"J Munoz","year":"2014","unstructured":"Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 2014;6:592\u2013603.","journal-title":"Oncotarget"},{"key":"2676_CR209","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12609-014-0140-5","volume":"6","author":"E Lim","year":"2014","unstructured":"Lim E, et al. Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy. Curr Breast Cancer Rep. 2014;6:71\u20138.","journal-title":"Curr Breast Cancer Rep"},{"key":"2676_CR210","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/bcr3599","volume":"16","author":"DR Cochrane","year":"2014","unstructured":"Cochrane DR, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16:R7.","journal-title":"Breast Cancer Res"},{"key":"2676_CR211","doi-asserted-by":"crossref","unstructured":"Giovannelli P, et al. The Androgen Receptor in Breast Cancer. Front Endocrinol. 2018;9:492.","DOI":"10.3389\/fendo.2018.00492"},{"key":"2676_CR212","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(24)00004-4","volume":"25","author":"C Palmieri","year":"2024","unstructured":"Palmieri C, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024;25:317\u201325.","journal-title":"Lancet Oncol"},{"key":"2676_CR213","unstructured":"GTx. A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+\/AR+ Breast Cancer (BC) in Postmenopausal Women. 2020. https:\/\/clinicaltrials.gov\/study\/NCT02463032."},{"key":"2676_CR214","doi-asserted-by":"crossref","unstructured":"Rinn K, et al. Abstract PO4-27-06: Design of Active Phase 3 ENABLAR-2 Study Evaluating Enobosarm +\/- Abemaciclib in Patients with AR\u2009+\u2009ER+HER2- 2nd-Line Metastatic Breast Cancer Following Tumor Progression on an Estrogen Blocking Agent Plus Palbociclib or Ribociclib. Cancer Res. 2024;84:PO4-27-06.","DOI":"10.1158\/1538-7445.SABCS23-PO4-27-06"},{"key":"2676_CR215","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, et al. Enzalutamide for the Treatment of Androgen Receptor\u2013Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018;36:884\u201390.","journal-title":"J Clin Oncol"},{"key":"2676_CR216","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/onco.13583","volume":"26","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, et al. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple\u2010Negative Breast Cancer. Oncologist. 2021;26:99\u2013e217.","journal-title":"Oncologist"},{"key":"2676_CR217","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s13277-014-2709-z","volume":"36","author":"X Yu","year":"2015","unstructured":"Yu X, et al. Androgen receptor signaling regulates growth of glioblastoma multiforme in men. Tumour Biol. 2015;36:967\u201372.","journal-title":"Tumour Biol"},{"key":"2676_CR218","doi-asserted-by":"crossref","unstructured":"Zhao N, et al. Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma. Front Oncol. 2021;11:616541.","DOI":"10.3389\/fonc.2021.616625"},{"key":"2676_CR219","doi-asserted-by":"crossref","unstructured":"Yang J-D, Chen J-T, Liu S-H, Chen R-M. Contribution of the testosterone androgen receptor\u2013PARD3B signaling axis to tumorigenesis and malignance of glioblastoma multiforme through stimulating cell proliferation and colony formation. J Clin Med. 2022;11:2757.","DOI":"10.3390\/jcm11164818"},{"key":"2676_CR220","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.euf.2020.10.002","volume":"7","author":"K Kourbanhoussen","year":"2021","unstructured":"Kourbanhoussen K, et al. Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. Eur Urol Focus. 2021;7:1044\u201351.","journal-title":"Eur Urol Focus"},{"key":"2676_CR221","doi-asserted-by":"publisher","first-page":"12665","DOI":"10.18632\/oncotarget.2851","volume":"5","author":"K Izumi","year":"2014","unstructured":"Izumi K, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget. 2014;5:12665\u201374.","journal-title":"Oncotarget"},{"key":"2676_CR222","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41419-025-07350-4","volume":"16","author":"M Di Donato","year":"2025","unstructured":"Di Donato M, et al. Role of the androgen receptor in melanoma aggressiveness. Cell Death Dis. 2025;16:34.","journal-title":"Cell Death Dis"},{"key":"2676_CR223","doi-asserted-by":"publisher","unstructured":"Boibessot C, Toren P. Sex steroids in the tumor microenvironment and prostate cancer progression. 2018. https:\/\/doi.org\/10.1530\/ERC-17-0493.","DOI":"10.1530\/ERC-17-0493"},{"key":"2676_CR224","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ccell.2020.07.007","volume":"38","author":"JJ Orme","year":"2020","unstructured":"Orme JJ, Huang H. Microenvironment-Mediated Resistance to Anti-Androgen Therapy. Cancer Cell. 2020;38:155\u20137.","journal-title":"Cancer Cell"},{"issue":"25","key":"2676_CR225","doi-asserted-by":"publisher","first-page":"00257","DOI":"10.1016\/j.tips.2025.11.003","volume":"S0165\u20136147","author":"DA Bader","year":"2025","unstructured":"Bader DA, Chakraborty B, McDonnell DP, Hirschey MD. Targeting androgen receptor signaling to enhance cancer immunotherapy. Trends Pharmacol Sci. 2025;S0165\u20136147(25):00257\u20133. https:\/\/doi.org\/10.1016\/j.tips.2025.11.003.","journal-title":"Trends Pharmacol Sci"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02676-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:11:36Z","timestamp":1782792696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02676-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":225,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2676"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02676-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects have written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}